<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604798</url>
  </required_header>
  <id_info>
    <org_study_id>ZSCG-001</org_study_id>
    <secondary_id>30973416</secondary_id>
    <nct_id>NCT01604798</nct_id>
  </id_info>
  <brief_title>Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer</brief_title>
  <official_title>Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC).
      Therefore, it is urgent that accurate and reliable serum biomarkers be identified.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetic bead-based fractionation coupled with matrix-assisted laser
      desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen
      serum samples from CRC patients and healthy controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum peptide mass fingerprinting (PMF)</measure>
    <time_frame>2010.03-2012.05 (2 years)</time_frame>
    <description>Compare PMF of the colorectal caner group and control group, and then build the model to distinguish patients with colorectal cancer and controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expressed peptide peaks</measure>
    <time_frame>2010.03-2012.05 (2 years)</time_frame>
    <description>Find differentially expressed peptide peaks from the model and identify some ideal serum biomarkers for the early diagnosis of colorectal cancer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">547</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <description>Patients with histologically confirmed colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum proteomics</intervention_name>
    <description>magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry</description>
    <arm_group_label>Colorectal Cancer Patients</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>MB coupled with MALDI-TOF MS</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All fasting blood samples were prepared without anticoagulant and left to clot at room
      temperature for 1.5 h. The serum was then isolated by centrifugation at 3000 g for 10 min at
      room temperature and stored at -80â„ƒ. All samples were subjected to one freeze-thaw cycle.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All of the CRC serum samples were obtained from patients with histologically confirmed
        colorectal cancer in the Department of General Surgery, Zhongshan Hospital, Fudan
        University, China. The control samples were collected from healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with colorectal cancer

        Inclusion criteria

          -  histologically confirmed colorectal cancer

          -  aged 18 years or older

          -  have provided written informed consent

        Exclusion criteria

          -  refusal to participate

        Healthy controls

        Inclusion criteria

          -  no cancer history

          -  aged 18 years or older

          -  have provided written informed consent

        Exclusion criteria

          -  refusal to participate

          -  have first-degree relative with a known history of colorectal cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Xu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006 Jan;116(1):271-84.</citation>
    <PMID>16395409</PMID>
  </reference>
  <reference>
    <citation>Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003 Apr;3(4):267-75. Review.</citation>
    <PMID>12671665</PMID>
  </reference>
  <reference>
    <citation>Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem. 2005 Dec;51(12):2236-44. Epub 2005 Oct 20.</citation>
    <PMID>16239339</PMID>
  </reference>
  <reference>
    <citation>Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope. 2008 Jan;118(1):61-8.</citation>
    <PMID>18043497</PMID>
  </reference>
  <reference>
    <citation>Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF 3rd, Liotta LA. Serum proteomics in cancer diagnosis and management. Annu Rev Med. 2004;55:97-112. Review.</citation>
    <PMID>14746511</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Professor of General Surgery</investigator_title>
  </responsible_party>
  <keyword>proteomics</keyword>
  <keyword>serum peptides</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>MALDI-TOF MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

